Test your novel Parkinson’s disease therapeutics aimed at targeting intracellular lysosomal pathways using in vivo models with GBA-associated mutations
Approximately 5-15% of PD patients have mutations in the GBA gene, making it the most important genetic risk factor for PD. Mouse models that express GBA with PD-associated mutations are attractive models for studying therapeutics that target intracellular lysosomal pathways for the treatment of PD.
Take advantage of InnoSer’s profound experience, for example with repeated or chronic intra-ventricular infusions to test new enzyme replacement therapies (ERT) in GBA mouse models. Our in-house neurology experts have long-standing experience with modelling PD in vivo and take a collaborative and flexible approach to guide your decision on choosing the best model fit for your current research goals.
Alpha-synuclein seeding models that InnoSer offers:
- Transgenic mouse model with human GBA with disease-associated mutations (e.g., D409V).
- Combination of GBA models with alpha-synuclein models (e.g., seeding).
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Test the efficacy of your treatments with the following biological readouts:
- MSD (e.g. GBA1 levels)
- HPLC-MS (Glucocerebrosidase / GCase, glucosylsphingosine)
- Immunofluorescence and FISH
Related Parkinson’s Disease model options
Transgenic Alpha-Synuclein Models
MPTP Induced PD Models
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know